Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever.

ABSTRACT:

Introduction

This open-label pilot study aimed to investigate the efficacy of canakinumab in colchicine-resistant familial Mediterranean fever (FMF) patients.

Method

Patients with one or more attacks in a month in the preceding 3 months despite colchicine were eligible to enter a 30-day run-in period. Patients who had an attack during the first run-in period advanced to a second 30-day period. At the first attack, patients started to receive three canakinumab 150 mg subcutaneous injections at 4-week intervals, and were then followed for an additional 2 months. Primary efficacy outcome measure was the proportion of patients with 50 % or more reduction in attack frequency. Secondary outcome measures included time to next attack following last canakinumab dose and changes in qu

SUBMITTER: Gul A 

PROVIDER: S-EPMC4559892 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature